449 related articles for article (PubMed ID: 21075282)
1. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in β-thalassemia.
Gardenghi S; Grady RW; Rivella S
Hematol Oncol Clin North Am; 2010 Dec; 24(6):1089-107. PubMed ID: 21075282
[TBL] [Abstract][Full Text] [Related]
2. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.
Ginzburg Y; Rivella S
Blood; 2011 Oct; 118(16):4321-30. PubMed ID: 21768301
[TBL] [Abstract][Full Text] [Related]
3. Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models.
Ramos P; Melchiori L; Gardenghi S; Van-Roijen N; Grady RW; Ginzburg Y; Rivella S
Ann N Y Acad Sci; 2010 Aug; 1202():24-30. PubMed ID: 20712768
[TBL] [Abstract][Full Text] [Related]
4. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.
Schmidt PJ; Toudjarska I; Sendamarai AK; Racie T; Milstein S; Bettencourt BR; Hettinger J; Bumcrot D; Fleming MD
Blood; 2013 Feb; 121(7):1200-8. PubMed ID: 23223430
[TBL] [Abstract][Full Text] [Related]
5. Hepcidin and Hfe in iron overload in beta-thalassemia.
Gardenghi S; Ramos P; Follenzi A; Rao N; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S
Ann N Y Acad Sci; 2010 Aug; 1202():221-5. PubMed ID: 20712796
[TBL] [Abstract][Full Text] [Related]
6. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.
Gardenghi S; Ramos P; Marongiu MF; Melchiori L; Breda L; Guy E; Muirhead K; Rao N; Roy CN; Andrews NC; Nemeth E; Follenzi A; An X; Mohandas N; Ginzburg Y; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S
J Clin Invest; 2010 Dec; 120(12):4466-77. PubMed ID: 21099112
[TBL] [Abstract][Full Text] [Related]
7. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models.
Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G
Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567
[TBL] [Abstract][Full Text] [Related]
8. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study.
Pasricha SR; Frazer DM; Bowden DK; Anderson GJ
Blood; 2013 Jul; 122(1):124-33. PubMed ID: 23656728
[TBL] [Abstract][Full Text] [Related]
9. Exogenous iron increases hemoglobin in beta-thalassemic mice.
Ginzburg YZ; Rybicki AC; Suzuka SM; Hall CB; Breuer W; Cabantchik ZI; Bouhassira EE; Fabry ME; Nagel RL
Exp Hematol; 2009 Feb; 37(2):172-83. PubMed ID: 19059700
[TBL] [Abstract][Full Text] [Related]
10. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
11. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.
Gardenghi S; Marongiu MF; Ramos P; Guy E; Breda L; Chadburn A; Liu Y; Amariglio N; Rechavi G; Rachmilewitz EA; Breuer W; Cabantchik ZI; Wrighting DM; Andrews NC; de Sousa M; Giardina PJ; Grady RW; Rivella S
Blood; 2007 Jun; 109(11):5027-35. PubMed ID: 17299088
[TBL] [Abstract][Full Text] [Related]
12. Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice.
Li H; Choesang T; Bao W; Chen H; Feola M; Garcia-Santos D; Li J; Sun S; Follenzi A; Pham P; Liu J; Zhang J; Ponka P; An X; Mohandas N; Fleming RE; Rivella S; Li G; Ginzburg YZ
Blood; 2017 Mar; 129(11):1514-1526. PubMed ID: 28151426
[TBL] [Abstract][Full Text] [Related]
13. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia.
Nai A; Pagani A; Mandelli G; Lidonnici MR; Silvestri L; Ferrari G; Camaschella C
Blood; 2012 May; 119(21):5021-9. PubMed ID: 22490684
[TBL] [Abstract][Full Text] [Related]
14. A tincture of hepcidin cures all: the potential for hepcidin therapeutics.
Bartnikas TB; Fleming MD
J Clin Invest; 2010 Dec; 120(12):4187-90. PubMed ID: 21099105
[TBL] [Abstract][Full Text] [Related]
15. RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia.
Schmidt PJ; Liu K; Visner G; Fitzgerald K; Fishman S; Racie T; Hettinger JL; Butler JS; Fleming MD
Am J Hematol; 2018 Jun; 93(6):745-750. PubMed ID: 29498084
[TBL] [Abstract][Full Text] [Related]
16. Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera.
Casu C; Oikonomidou PR; Chen H; Nandi V; Ginzburg Y; Prasad P; Fleming RE; Shah YM; Valore EV; Nemeth E; Ganz T; MacDonald B; Rivella S
Blood; 2016 Jul; 128(2):265-76. PubMed ID: 27154187
[TBL] [Abstract][Full Text] [Related]
17. Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.
Casu C; Pettinato M; Liu A; Aghajan M; Lo Presti V; Lidonnici MR; Munoz KA; O'Hara E; Olivari V; Di Modica SM; Booten S; Guo S; Neil G; Miari R; Shapir N; Zafir-Lavie I; Domev H; Ferrari G; Sitara D; Nai A; Rivella S
Blood; 2020 Oct; 136(17):1968-1979. PubMed ID: 32556142
[TBL] [Abstract][Full Text] [Related]
18. Regulation of hepcidin and iron-overload disease.
Lee PL; Beutler E
Annu Rev Pathol; 2009; 4():489-515. PubMed ID: 19400694
[TBL] [Abstract][Full Text] [Related]
19. Hepcidin levels and iron status in beta-thalassemia major patients with hepatitis C virus infection.
Hendy OM; Allam M; Allam A; Attia MH; El Taher S; Eldin MM; Ali A
Egypt J Immunol; 2010; 17(2):33-44. PubMed ID: 23082485
[TBL] [Abstract][Full Text] [Related]
20. Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.
Schmidt PJ; Fleming MD
Hematol Oncol Clin North Am; 2014 Apr; 28(2):387-401. PubMed ID: 24589273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
